Pricing Log in Create free account
Friday 6 November 2026 Export BBIO’s income statement to Excel — free account

BridgeBio Pharma, Inc.

BBIO Healthcare Biotechnology

BridgeBio Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.1 million, up 126.3% from fiscal 2024.

Revenue
+192.6%
EPS
+55.8%
Free cash flow
+60.5%
Total debt
+4.21%

Quarter to September 2026, against a year earlier

74.06 0.21 −0.28%
Market cap
$14.5B
P/E
0.0×
Fwd P/E
−27.5×
Dividend yield
—
F-score
3/9
Altman Z
−3.45
Beneish M
8.17
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

BridgeBio Pharma, Inc. 10-Q filed Aug 10, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 4:31 PM ET · Document on sec.gov · Filing index

Nothing in this filing raised a red flag. The document itself is on sec.gov.

Read the filing on sec.gov